

Ilias Karaiskos

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3461304/ilias-karaiskos-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55
papers

3,049
citations

28
h-index

55
g-index

66
ext. papers

3,820
ext. citations

7.3
avg, IF

5.3
L-index

#	Paper	IF	Citations
55	Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulization of CMS among patients with ventilator-associated pneumonia.. <i>International Journal of Antimicrobial Agents</i> , 2022 , 106588	14.3	1
54	Multidrug-resistant : mechanisms of resistance including updated data for novel β -lactam- β -lactamase inhibitor combinations. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 19, 1457-1468	5.5	7
53	Carbapenemase producing : implication on future therapeutic strategies. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 1-17	5.5	10
52	Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing <i>Klebsiella pneumoniae</i> of sequence type 39 during treatment. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021 , 40, 219-224	5.3	16
51	Ceftazidime/avibactam in the era of carbapenemase-producing <i>Klebsiella pneumoniae</i> : experience from a national registry study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021 , 76, 775-783	5.1	14
50	Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9	7
49	Carbapenem-Sparing Strategies for ESBL Producers: When and How. <i>Antibiotics</i> , 2020 , 9,	4.9	33
48	Outbreak of KPC-2-producing endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019. <i>Eurosurveillance</i> , 2020 , 25,	19.8	17
47	ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study. <i>JMIR MHealth and UHealth</i> , 2020 , 8, e20525	5.5	1
46	In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR <i>Pseudomonas aeruginosa</i> isolates from Greece. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2164-2172	5.1	4
45	Lipid A profiling and metabolomics analysis of paired polymyxin-susceptible and -resistant MDR <i>Klebsiella pneumoniae</i> clinical isolates from the same patients before and after colistin treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2852-2863	5.1	4
44	De-escalation of antimicrobial therapy in ICU settings with high prevalence of multidrug-resistant bacteria: a multicentre prospective observational cohort study in patients with sepsis or septic shock. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 3665-3674	5.1	9
43	Evaluation of in vitro methods for testing tigecycline combinations against carbapenemase-producing <i>Klebsiella pneumoniae</i> isolates. <i>Journal of Global Antimicrobial Resistance</i> , 2020 , 20, 98-104	3.4	1
42	International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of	5.8	280
41	The "Old" and the "New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. <i>Frontiers in Public Health</i> , 2019 , 7, 151	6	107
40	Oral fosfomycin for the treatment of chronic bacterial prostatitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1430-1437	5.1	19
39	Nationwide epidemiology of carbapenem resistant <i>Klebsiella pneumoniae</i> isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance. <i>BMC Infectious Diseases</i> , 2019 , 19, 167	4	48

38	Multifaceted mechanisms of colistin resistance revealed by genomic analysis of multidrug-resistant <i>Klebsiella pneumoniae</i> isolates from individual patients before and after colistin treatment. <i>Journal of Infection</i> , 2019 , 79, 312-321	18.9	14
37	In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing <i>Klebsiella pneumoniae</i> isolated in Greek hospitals in 2015-2016. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019 , 38, 1143-1150	5.3	21
36	Novel β -lactam- β -lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019 , 15, 133-149	5.5	49
35	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing <i>Escherichia coli</i> and ESBL-Producing <i>Klebsiella pneumoniae</i> . <i>Infection Control and Hospital Epidemiology</i> , 2018 , 39, 660-667	2	29
34	Management of KPC-producing <i>Klebsiella pneumoniae</i> infections. <i>Clinical Microbiology and Infection</i> , 2018 , 24, 133-144	9.5	98
33	Evaluation of ComASP (Colistin) (formerly SensiTest (Colistin)), a commercial broth microdilution-based method to evaluate the colistin minimum inhibitory concentration for carbapenem-resistant <i>Klebsiella pneumoniae</i> isolates. <i>Journal of Global Antimicrobial Resistance</i> , 2018 , 15, 123-126	3.4	6
32	Epidemiology and resistance phenotypes of carbapenemase-producing in Greece, 2014 to 2016. <i>Eurosurveillance</i> , 2018 , 23,	19.8	39
31	Multifactorial chromosomal variants regulate polymyxin resistance in extensively drug-resistant <i>Klebsiella pneumoniae</i> . <i>Microbial Genomics</i> , 2018 , 4,	4.4	28
30	Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β -lactamase-producing Enterobacteriaceae. <i>International Journal of Antimicrobial Agents</i> , 2018 , 52, 577-585	14.3	23
29	Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing <i>Klebsiella pneumoniae</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017 , 36, 1305-1315	5.3	36
28	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. <i>Lancet Infectious Diseases</i> , 2017 , 17, 726-734	25.5	268
27	Point-prevalence survey of healthcare facility-onset healthcare-associated <i>Clostridium difficile</i> infection in Greek hospitals outside the intensive care unit: The C. DEFINE study. <i>PLoS ONE</i> , 2017 , 12, e0182799	3.7	5
26	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. <i>International Journal of Antimicrobial Agents</i> , 2017 , 50, 664-672	14.3	8
25	Combination therapy for extensively-drug resistant gram-negative bacteria. <i>Expert Review of Anti-Infective Therapy</i> , 2017 , 15, 1123-1140	5.5	26
24	Colistin: still a lifesaver for the 21st century?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017 , 13, 59-71	5.5	66
23	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. <i>Clinical Infectious Diseases</i> , 2017 , 65, 1615-1623	11.6	33
22	Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2016 , 48, 337-41	14.3	21
21	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1672-80	5.1	33

20	Nationwide surveillance of resistance rates of <i>Staphylococcus aureus</i> clinical isolates from Greek hospitals, 2012-2013. <i>Infectious Diseases</i> , 2016 , 48, 287-292	3.1	9
19	A Multinational, Preregistered Cohort Study of β -Lactam/ β -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 4159-69	5.9	96
18	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. <i>Mayo Clinic Proceedings</i> , 2016 , 91, 1362-1371	6.4	66
17	Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 6471-6	5.9	48
16	Plazomicin: an investigational therapy for the treatment of urinary tract infections. <i>Expert Opinion on Investigational Drugs</i> , 2015 , 24, 1501-11	5.9	30
15	Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 7240-8	5.9	76
14	High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections. <i>International Journal of Antimicrobial Agents</i> , 2015 , 45, 90-3	14.3	34
13	Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. <i>International Journal of Antimicrobial Agents</i> , 2014 , 43, 52-9	14.3	155
12	Large vessel vasculitis in a patient with acute Q-fever: A case report. <i>IDCases</i> , 2014 , 1, 56-9	2	9
11	Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 1351-70	4	189
10	Nosocomial dissemination of <i>Providencia stuartii</i> isolates producing extended-spectrum β -Lactamases VEB-1 and SHV-5, metallo- β -Lactamase VIM-1, and RNA methylase RmtB. <i>Journal of Global Antimicrobial Resistance</i> , 2013 , 1, 115-116	3.4	8
9	Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 2388-90	5.9	92
8	Successful treatment of extensively drug-resistant <i>Acinetobacter baumannii</i> ventriculitis and meningitis with intraventricular colistin after application of a loading dose: a case series. <i>International Journal of Antimicrobial Agents</i> , 2013 , 41, 480-3	14.3	39
7	Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant <i>Acinetobacter baumannii</i> ventriculitis and meningitis: a literature review. <i>International Journal of Antimicrobial Agents</i> , 2013 , 41, 499-508	14.3	102
6	Colistin methanesulfonate and colistin pharmacokinetics in critically ill patients receiving continuous venovenous hemodiafiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 668-71	5.9	65
5	Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 4241-9	5.9	171
4	Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. <i>Journal of Critical Care</i> , 2011 , 26, 331.e1-7	4	37
3	Acute uncomplicated cystitis: from surveillance data to a rationale for empirical treatment. <i>International Journal of Antimicrobial Agents</i> , 2010 , 35, 62-7	14.3	28

- | | | | |
|---|---|-----|-----|
| 2 | Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 3430-6 | 5.9 | 396 |
| 1 | Severe dysphagia as the presenting symptom of Wernicke-Korsakoff syndrome in a non-alcoholic man. <i>Neurological Sciences</i> , 2008 , 29, 45-6 | 3.5 | 9 |